Skip to Main Content
Contribute Try STAT+ Today

Gilead Sciences (GILD), which is already the subject of red-hot attention for its business practices, is about to come under still more scrutiny when a House committee holds a hearing on Thursday about pricing for its Truvada HIV prevention pill. And Gilead chief executive Daniel O’Day will be among those testifying.

AIDS activists have increasingly lambasted the company for pricing they claim has caused access issues and have implored the federal government to pursue royalties on a key patent that was filed by researchers whose work was funded, in part, with taxpayer dollars. The activists argue that the government could use any royalties toward combating the virus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.